X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ALKEM LABORATORIES ALEMBIC PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 29.0 - - View Chart
P/BV x 6.6 7.4 89.2% View Chart
Dividend Yield % 0.7 0.6 121.8%  

Financials

 ALEMBIC PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ALKEM LABORATORIES
Mar-16
ALEMBIC PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs7921,589 49.8%   
Low Rs4431,232 36.0%   
Sales per share (Unadj.) Rs167.0417.5 40.0%  
Earnings per share (Unadj.) Rs38.256.3 67.8%  
Cash flow per share (Unadj.) Rs42.064.7 64.9%  
Dividends per share (Unadj.) Rs4.0012.70 31.5%  
Dividend yield (eoy) %0.60.9 72.0%  
Book value per share (Unadj.) Rs84.9292.9 29.0%  
Shares outstanding (eoy) m188.52119.57 157.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.4 109.4%   
Avg P/E ratio x16.225.1 64.6%  
P/CF ratio (eoy) x14.721.8 67.4%  
Price / Book Value ratio x7.34.8 151.0%  
Dividend payout %10.522.6 46.5%   
Avg Mkt Cap Rs m116,383168,653 69.0%   
No. of employees `000NANA-   
Total wages/salary Rs m4,2149,171 45.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,48749,915 63.1%  
Other income Rs m551,645 3.3%   
Total revenues Rs m31,54251,561 61.2%   
Gross profit Rs m10,0608,482 118.6%  
Depreciation Rs m7221,006 71.8%   
Interest Rs m37671 5.5%   
Profit before tax Rs m9,3568,451 110.7%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,606 134.5%   
Profit after tax Rs m7,1946,731 106.9%  
Gross profit margin %31.917.0 188.0%  
Effective tax rate %23.119.0 121.5%   
Net profit margin %22.813.5 169.4%  
BALANCE SHEET DATA
Current assets Rs m15,06627,062 55.7%   
Current liabilities Rs m7,67415,324 50.1%   
Net working cap to sales %23.523.5 99.8%  
Current ratio x2.01.8 111.2%  
Inventory Days Days6767 100.7%  
Debtors Days Days4141 98.4%  
Net fixed assets Rs m8,23712,610 65.3%   
Share capital Rs m377239 157.7%   
"Free" reserves Rs m15,41634,490 44.7%   
Net worth Rs m16,00535,027 45.7%   
Long term debt Rs m01,212 0.0%   
Total assets Rs m24,59454,387 45.2%  
Interest coverage x255.213.6 1,876.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.9 139.5%   
Return on assets %29.413.6 216.0%  
Return on equity %44.919.2 233.9%  
Return on capital %58.724.9 236.1%  
Exports to sales %55.712.9 430.6%   
Imports to sales %10.43.1 337.9%   
Exports (fob) Rs m17,5516,461 271.6%   
Imports (cif) Rs m3,2831,540 213.1%   
Fx inflow Rs m17,8116,563 271.4%   
Fx outflow Rs m5,3183,012 176.6%   
Net fx Rs m12,4933,552 351.7%   
CASH FLOW
From Operations Rs m9,3047,259 128.2%  
From Investments Rs m-3,1051,864 -166.5%  
From Financial Activity Rs m-1,959-9,273 21.1%  
Net Cashflow Rs m4,240-150 -2,826.7%  

Share Holding

Indian Promoters % 74.1 66.9 110.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 33.1 8.8%  
FIIs % 9.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 0.0 -  
Shareholders   49,328 68,381 72.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - CIPLA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS